• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Myriad Genetics Inc. (Amendment)

    2/14/24 8:24:26 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email
    SC 13G/A 1 CamberMYGN13Ga2024.htm PRIMARY DOCUMENT  
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)
     
    Myriad Genetics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     
    62855J104
    (CUSIP Number)
     
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)62855J104
    ☒  Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
    Persons who respond to the collection of information contained in this form are not
    required to respond unless the form displays a currently valid OMB control number.
     
    13G
    CUSIP No. 62855J104
    Page 2 of 6
     
                                                 
    1. Names of Reporting Persons.
    Camber Capital Management LP
    42-1693587
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Delaware
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    7,635,000 shares
     
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    7,635,000 shares
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Camber Capital Management LP – 7,635,000 shares
        10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Camber Capital Management LP – 8.5%
    12. Type of Reporting Person
    Camber Capital Management LP – 00 (Limited Partnership)
     
    13G
    CUSIP No.   62855J104
    Page 3 of 6

    1. Names of Reporting Persons.
    Stephen DuBois
    Not applicable
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Stephen DuBois – United States
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    7,635,000 shares
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    7,635,000 shares
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Stephen DuBois – 7,635,000 shares
       10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Stephen DuBois – 8.5%
    12. Type of Reporting Person
    Stephen DuBois – IN
     
    13G
      CUSIP No.   62855J104
    Page 4 of 6
     
     
     
    ITEM 1.
    (a) Name of Issuer:
    Myriad Genetics Inc
     
    (b) Address of Issuer's Principal Executive Offices:
    322 North 2200 West, Salt Lake City, UT 84116
    ITEM 2.
    (a) Name of Person Filing:
    Camber Capital Management LP
    Stephen DuBois
     
    (b) Address of Principal Business Office, or if None, Residence:
    Camber Capital Management LP
    Stephen DuBois
    101 Huntington Avenue
    Suite 2101
    Boston, MA 02199
     
    (c) Citizenship:
    Camber Capital Management LP – Delaware
    Stephen DuBois – United States
     
    (d) Title of Class of Securities:
    Common Stock, par value $0.01 per share
     
    (e) CUSIP Number:
    62855J104
     
     
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
     
     
    (a)
    [_]
    Broker or dealer registered under Section 15 of the Act  (15 U.S.C. 78o).
     
    (b)
    [_]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).   
     
    (c)
    [_]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).   
     
    (d)
    [_]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [_]
    An investment adviser in accordance with  ss.240.13d-1(b)(1)(ii)(E);   
     
    (f)
    [_]
    An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);   
     
    (g)
    [_]
    A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);   
     
    (h)
    [_]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);   
     
    (i)
    [_]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);   
     
    (j)
    [_]
    Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
     
    ITEM 4. OWNERSHIP.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
    (a) Amount beneficially owned: Camber Capital Management LP – 7,635,000 shares
    Stephen DuBois – 7,635,000 shares
     
    (b) Percent of class: Camber Capital Management LP – 8.5% 
    Stephen DuBois – 8.5%
     
     
    13G
       CUSIP No.   62855J104
    Page 5 of 6
     
    (c) Number of shares as to which such person has:
     
    (i) Sole power to vote or to direct the vote
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (ii) Shared power to vote or to direct the vote
    Camber Capital Management LP – 7,635,000 shares
    Stephen DuBois – 7,635,000 shares
     
    (iii) Sole power to dispose or to direct the disposition of
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (iv) Shared power to dispose or to direct the disposition of
    Camber Capital Management LP – 7,635,000 shares
    Stephen DuBois – 7,635,000 shares
     
     
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
     
     
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
     
    Not applicable
     
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
     
    Not applicable

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
     
    Not applicable
     
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
     
    Not applicable
     
     
    13G
    CUSIP No.   62855J104
    Page 6 of 6
     
     
     
    ITEM 10. CERTIFICATIONS.
    The following certification shall be included if the statement is filed pursuant to S.240.13d-1(c):
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
     
     
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    CAMBER CAPITAL MANAGEMENT LP
    By: /s/Sean George
    Sean George
    Chief Financial Officer
     
    STEPHEN DUBOIS
    By: /s/ Stephen DuBois
    Stephen DuBois, individually
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
     
     
    Get the next $MYGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/21/2025$6.00Sector Outperform → Sector Perform
    Scotiabank
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $MYGN
    SEC Filings

    View All

    SEC Form EFFECT filed by Myriad Genetics Inc.

    EFFECT - MYRIAD GENETICS INC (0000899923) (Filer)

    3/5/26 12:15:18 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 424B3 filed by Myriad Genetics Inc.

    424B3 - MYRIAD GENETICS INC (0000899923) (Filer)

    3/4/26 5:24:25 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-3 filed by Myriad Genetics Inc.

    S-3 - MYRIAD GENETICS INC (0000899923) (Filer)

    2/24/26 4:10:08 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Haas Kevin Richard covered exercise/tax liability with 22,310 shares, decreasing direct ownership by 11% to 180,022 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/16/26 5:58:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Scientific Officer Muzzey Dale was granted 173,196 shares and covered exercise/tax liability with 37,799 shares, increasing direct ownership by 70% to 329,275 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/16/26 5:06:03 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief People Officer Solaiman Shereen was granted 173,196 shares and covered exercise/tax liability with 14,683 shares, increasing direct ownership by 145% to 267,801 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/16/26 5:06:09 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Myriad Genetics downgraded by Scotiabank with a new price target

    Scotiabank downgraded Myriad Genetics from Sector Outperform to Sector Perform and set a new price target of $6.00

    5/21/25 8:40:26 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics downgraded by Wolfe Research

    Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

    5/8/25 8:27:12 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

    5/7/25 8:36:31 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

    SALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer. This approval is based on final data from the PRIMA trial, where the MyChoice CDx Test determined homologous recombination deficiency (HRD) status and was used to stratify advanced ovarian cancer patients. The MyChoice CDx is the only FDA-approved companion diagnostic test in the United States to identify patie

    3/17/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Myriad Commercially Launches Precise MRD with Select Community Oncologists

    SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. "The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low levels, the Precise MRD test will enable earlier insight and more informed treatment decisions," said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. "This launch demonstrates the new Myriad's ability

    3/2/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Raha Samraat S. bought $199,844 worth of shares (40,000 units at $5.00), increasing direct ownership by 9% to 493,104 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/9/26 7:03:13 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Financials

    Live finance-specific insights

    View All

    Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

    Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin was 70.0% and in-line with third quarter 2025. Fourth quarter 2025 GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and ad

    2/23/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2025. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please reg

    2/16/26 4:15:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

    SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference. Select Preliminary Four

    1/12/26 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

    SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

    11/14/24 4:16:31 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Myriad Genetics Inc.

    SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    5/1/24 4:21:33 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Myriad Genetics Inc.

    SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    4/25/24 4:18:40 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

    SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scott Leffler, who has served as Chief Financial Officer since January 2024, will transition to a consulting role serving the CEO and the Board of D

    8/18/25 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care